WIN Metals Ltd (ASX:WIN)

Verve Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2020	Jun 30, 2019
Selling, General & Admin	1.35	1.27	1.32	0.82	0.03	0.03
Other Operating Expenses	0.15	0.2	0.21	0.1	-	-
Operating Expenses	33.46	2.44	2.26	1.89	0.03	0.03
Operating Income	-34.44	-2.44	-2.26	-1.89	-0.03	-0.03
Interest Expense	-0.01	-0.01	-0.01	-0.01	-	-
Interest & Investment Income	0.03	0.12	0.22	0.04	-	-
Other Non Operating Income (Expenses)	0.03	0.03	0	-0.19	-	-
EBT Excluding Unusual Items	-34.39	-2.3	-2.06	-2.04	-0.03	-0.03
Pretax Income	-33.74	-2.3	-2.06	-2.04	-0.03	-0.03
Net Income	-33.74	-2.3	-2.06	-2.04	-0.03	-0.03
Net Income to Common	-33.74	-2.3	-2.06	-2.04	-0.03	-0.03
Shares Outstanding (Basic)	348	301	255	173	130	-
Shares Outstanding (Diluted)	348	301	255	173	130	-
Shares Change (YoY)	25.80%	17.86%	47.27%	33.19%	-	-
EPS (Basic)	-0.10	-0.01	-0.01	-0.01	-0.00	-
EPS (Diluted)	-0.10	-0.01	-0.01	-0.01	-0.00	-
Free Cash Flow	-4.12	-11	-16.08	-5.58	-0.52	-0.74
Free Cash Flow Per Share	-0.01	-0.04	-0.06	-0.03	-0.00	-
EBITDA	-2.98	-1.78	-2.01	-1.86	-	-
D&A For EBITDA	31.46	0.66	0.25	0.02	-	-
EBIT	-34.44	-2.44	-2.26	-1.89	-0.03	-0.03

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.